Extract
Cardiovascular and respiratory diseases are major contributors to global deaths [1]. Although low lung function is a risk factor for early death, like hypertension and hypercholesterolaemia [2], evaluation of lung function in primary care is not prioritised as highly as blood pressure or cholesterol measurements [3]. Also, public health authorities have remained silent on major health challenges other than smoking relevant for development and preservation of normal lung function from birth to old age. It is now increasingly evident that low lung function in childhood may affect general health throughout life [4–8]. It therefore seems likely that improvement of lung function on a population-scale may be associated with lower morbidity and mortality. We therefore tested the hypothesis that supernormal lung function is associated with lower morbidity and mortality.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Çolak reports personal fees from Boehringer Ingelheim, AstraZeneca, and Sanofi Genzyme outside the submitted work.
Conflict of interest: Dr. Nordestgaard has nothing to disclose.
Conflict of interest: Dr. Vestbo reports personal fees from GlaxoSmithKline, Chiesi pharmaceuticals, Boehringer-Ingelheim, Novartis, Almirall, AstraZeneca, personal fees from Bioxydyn, personal fees from GlaxoSmithKline, Chiesi pharmaceuticals, Novartis, AstraZeneca, Boehringer-Ingelheim, personal fees from GlaxoSmithKline, AstraZeneca, Ferring, outside the submitted work.
Conflict of interest: Dr. Lange reports grants and personal fees from Almirall, grants and personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, personal fees from Novartis, grants and personal fees from GSK, personal fees from Nycomed, personal fees from Pfizer, personal fees from Mundipharma, outside the submitted work.
Conflict of interest: Dr. Afzal has nothing to disclose.
- Received September 3, 2020.
- Accepted November 13, 2020.
- Copyright ©ERS 2020
LIBRARY USERS
Log in through your institution
Purchase access
